Morning. I'm Alexandra MacLean, Chief Executive Officer and a member of the Board of Directors of Avenue Therapeutics Inc, and I will be presiding over today's virtual meeting of stockholders. On behalf of our company, I want to welcome you to our 2025 Annual Meeting of Stockholders, which is now formally called to order. We are very pleased to have each of you in attendance at today's virtual meeting. Let me begin by introducing the other directors of the company in attendance via remote communication. With us today are Jay Kranzler, M.D., Ph.D., the Chairman of our Board, Faith Charles, Neil Herskowitz, Curtis Oltmans, and Lindsay A. Rosenwald, M.D. Also present here today is Joseph Epstein of KPMG LLP, our independent auditors for the year ending December 31st, 2024. Rakesh Gopalan of Troutman Pepper Hamilton Sanders LLP, our legal counsel. David Jin, our Corporate Secretary, Chief Operating Officer, and Interim Chief Financial Officer, who will serve as Secretary of the Meeting. And Tony Carideo, who will serve as Inspector of Elections of the Meeting. Our order of business this morning will be to accept the motions to be considered, collect the votes, and then receive a report from the Inspector of Elections about the results. If you have any questions, please submit them using the online application on the virtual meeting website or email them to info@avenuetx.com, and we will address them after the meeting. This brings us to the first item on the agenda, which is the determination of a quorum. The bylaws provide that the presence, in person or by proxy, of a majority of the outstanding voting power of the company, calculated in accordance with the company's certificate of incorporation on the record date, constitutes a quorum. Mr. Carideo, do we have a quorum? Yes, you do. A majority of the outstanding voting power of the company, calculated in accordance with the company's certificate of incorporation as of the record date, November 25th, 2025, is represented at the meeting. Thank you, Mr. Carideo. There are three motions to be voted on by the stockholders. One, the first motion is the election of Jay Kranzler, Faith Charles, Neil Herskowitz, Alexandra MacLean, Curtis Oltmans, and Lindsay A. Rosenwald as directors to hold office until the annual meeting in 2026 or until their respective successors have been elected and qualified. Two, the second motion is to ratify the appointment of KPMG LLP as the company's independent registered public accounting firm for the 2025 fiscal year. All stockholders of record as of November 25, 2025, are entitled to vote at this virtual meeting and have the ability to do so online. If there is any stockholder of record as of November 25th, 2025, who has not voted by proxy and now wants to vote, or who has previously voted by proxy and now wants to change that vote, you may now vote online by following the instructions available on the virtual meeting website. If you have already sent in your proxy card or otherwise voted over the internet or by phone and do not want to change your vote, you do not need to do anything now. Okay. Then I'll now call the question on the following resolutions. Resolved that the following persons hereby are elected as directors of the company to serve until the 2026 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Lindsay A. Rosenwald, Faith Charles, Neil Herskowitz, Jay Kranzler, Alexandra MacLean, and Curtis Oltmans. Resolved that the appointment of KPMG LLP to serve as the company's independent registered public accounting firm for the 2025 fiscal year is hereby ratified. At this moment, I'm going to officially close the polls. I want to thank everyone for your participation. I'll now ask the Inspector of Elections to report on the vote. Dr. MacLean, based on the preliminary results, all of the nominees for director have been elected, and the motion to ratify the appointment of KPMG LLP as the company's independent registered public accounting firm for the 2025 fiscal year has been approved. Thank you, Mr. Carideo. That completes our formal business for today and concludes the 2025 Annual Stockholders' Meeting. Thank you for joining today and for your support of Avenue Therapeutics Inc. Let me now formally close this meeting. I will now open the floor to any questions to us or the representative from KPMG LLP, our independent registered public accounting firm. If you have any questions, please submit them using the online application on the virtual meeting website or email them to info@avenuetx.com, and we will address them after the meeting. We will now end this meeting. Thank you. This now concludes the meeting. Thank you for joining, and have a pleasant day.